Symposium on Drug-Drug Interactions
Drug-drug
interaction is one of the major problems in therapeutics
associated with the use of drugs.
Given the aging of the population, polymedication and the continuous development of new drugs, the occurrence of clinically significant drug-drug interactions
will dramatically increase. Metabolic enzymes as well as
drug transporters are frequently involved in DDI. In vitro-in vivo extrapolation
(IVIVE) methodology is widely used in
drug discovery and huge effort in both academia and industry has focused on
developing reliable methods to predict DDI. During this session, you will have
the opportunity to discuss with international experts in the field the state of
the art in predicting the magnitude of DDI at the individual level, the
clinical pertinence and the role of transporters in drug interactions.
EACPT Congress 2103
Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.
Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.
See here for more on
key themes of the Congress.
EACPT Geneva 2013 Congress website www.eacpt2013.org
EACPT Geneva 2013 Congress website www.eacpt2013.org
No comments:
Post a Comment